PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩10 per share · Prices as of the 2026-10-02 close
Ilshin Bio-Base saw a sharp year-on-year improvement in both revenue and profit in 2025, entering a recovery phase in demand for freeze dryers used by pharmaceutical and biotech customers.
2025 revenue reached KRW 14.53 billion (up 34.3% year-on-year), with operating profit of KRW 4.55 billion lifting the operating margin from the low-20% range to over 31%
In January 2026 the company secured large single supply contracts with Dongkwang Pharm (KRW 4.29 billion) and Ownerve (KRW 2.25 billion) in quick succession, signaling order momentum
Quarterly results show notable swings depending on contract recognition timing, with Q1 2026 revenue at KRW 2.52 billion versus Q2 2026 at KRW 4.17 billion
The debt ratio stays in the very low 5-9% range, reflecting a near debt-free structure and relatively high financial stability
Multiple research firms project the global freeze-drying equipment market to grow at roughly 5-8% annually, supporting a mid-to-long-term demand base
Ilshin Bio-Base, established in 1988 and listed on KOSDAQ in 2007, is a bio-equipment specialist that manufactures and sells freeze dryers and ultra-low temperature freezers based on vacuum, cryogenic, and control technologies.
Its product lineup ranges from small laboratory-scale models to large plant-type systems for pharmaceutical and food industry production, with core customers spanning pharmaceutical, vaccine, functional food, and cosmetics ingredient producers.
Recent contract announcements highlight demand from pharmaceutical and biotech clients such as Dongkwang Pharm, for an automated sterile freeze dryer, and Ownerve, for herbal pharmaceutical automation equipment.
Freeze dryers are not standardized mass-produced goods but are custom-built and installed per customer order, which causes revenue recognition to swing significantly by quarter depending on contract size.
The company operates a subsidiary dedicated to overseas sales and marketing, shifting from continental hub-based distribution to country-by-country direct sales to expand overseas revenue.
Domestically, the competitive landscape is shared among a small number of specialized manufacturers, while globally the company competes with larger players such as GEA, SP Industries, and Tofflon.
The company positions its long operating history, accumulated technology, and price competitiveness as core strengths in the domestic market.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩3.5B | ₩1.1B | 31.6% |
| 2025Q3 | ₩4.9B | ₩1.9B | 39.2% |
| 2025Q4 | ₩4.2B | ₩1.1B | 25.4% |
| 2026Q1 | ₩2.5B | ₩500M | 18.0% |
| 2026Q2 | ₩4.2B | ₩1.5B | 36.6% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩20.4B | ₩5.1B | ₩3.8B | 25.2% | 7.1% | 8.6% |
| 2023 | ₩16.4B | ₩6.2B | ₩6.2B | 37.8% | 10.9% | 6.2% |
| 2024 | ₩10.8B | ₩2.3B | ₩3.8B | 20.9% | 6.3% | 5.8% |
| 2025 | ₩14.5B | ₩4.5B | ₩4.8B | 31.3% | 7.4% | 5.8% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-23
Consolidated revenue in 2025 came to KRW 14.53 billion, up 34.3% from KRW 10.82 billion in 2024, while operating profit more than doubled to KRW 4.55 billion from KRW 2.26 billion, lifting the operating margin sharply from 20.9% to 31.3%.
Net income attributable to owners rose to KRW 4.79 billion from KRW 3.81 billion the prior year. Compared with 2023, when revenue reached KRW 16.44 billion and operating profit KRW 6.21 billion at a 37.8% margin, 2024 appears to have been a trough year, with 2025 representing a recovery phase.
By quarter, Q3 2025 delivered strong results with revenue of KRW 4.87 billion and operating profit of KRW 1.91 billion, before easing to revenue of KRW 4.23 billion and operating profit of KRW 1.08 billion in Q4 2025.
Q1 2026 revenue fell to KRW 2.52 billion with operating profit of KRW 0.45 billion, likely reflecting a gap in contract recognition, before improving again in Q2 2026 to revenue of KRW 4.17 billion and operating profit of KRW 1.53 billion.
Cumulative net income attributable to owners over the trailing four quarters, from Q3 2025 through Q2 2026, reached KRW 6.01 billion, exceeding the full prior-year figure and pointing to a sustained profit recovery over the past year. Even so, revenue scale remains below the 2022 peak of KRW 20.43 billion.
Freeze-drying (lyophilization) equipment has become an essential process for ensuring the stability and shelf life of pharmaceuticals, vaccines, and biologics, moving in tandem with growth in the pharmaceutical and biotech industries.
Multiple global market research firms project the freeze-drying equipment market to grow at an annual rate in the 5-8% range over the coming years, citing expanding production of biologics and vaccines as a key driver.
The Asia-Pacific region is classified as one of the relatively faster-growing regions in terms of growth rate, and domestic demand for related equipment continues alongside the expansion of biopharmaceutical contract manufacturing (CDMO).
On the competitive front, global majors such as GEA, Tofflon, SP Industries, and Azbil Telstar have been rolling out new products with advanced automation and digital monitoring features, intensifying technological competition.
Ilshin Bio-Base has built its position in the domestic market on long operating history and price competitiveness, but faces the challenge of overcoming gaps in technology and capital scale versus global players on large overseas projects.
Given the nature of the equipment, orders tend to cluster around customers' new capital investment cycles or GMP certification renewal timing, making the industry more sensitive to individual customer investment timing than to broad macro cycles.
Contracts disclosed since January 2026 with Dongkwang Pharm (worth KRW 4.29 billion, running through February 2027) and Ownerve (KRW 2.25 billion, through September 2026) represent 39.7% and 20.8% of 2024 revenue respectively, and could meaningfully contribute to future revenue recognition.
The company has stated it is shifting from continental hub-based overseas distribution to country-by-country direct sales, strengthening localized marketing through new product development and customer technical support.
Its stated production capacity of over 200 freeze dryers annually supports its ability to respond to additional orders. However, the timing and scale of future large orders and the pace of overseas revenue expansion have not yet been specified in disclosures or formal guidance, warranting continued monitoring.
Given the contract-based revenue structure, quarterly results are likely to continue showing concentrated patterns, making an annual cumulative view more informative than reading quarter-to-quarter swings as deterioration.
With the global freeze-drying equipment market's growth outlook intact, whether domestic pharmaceutical and biotech companies resume capital investment stands out as a key variable for the mid-term order pipeline.
The recent earnings recovery has clearly lifted profit levels from the 2024 trough, and cumulative net income over the trailing four quarters has also outpaced the preceding full-year result.
Market data indicates the share price sits at a relatively low level versus its historical trading range when measured against net asset value, which can be interpreted as a discount to book value.
Dividends have been paid consistently each year, but the absolute payout remains modest, suggesting earnings improvement is likely a more decisive driver of share performance than dividend appeal.
Given the contract-based business structure that produces large quarter-to-quarter earnings swings, it is more informative to examine annual cumulative results and order flow together rather than reading any single-point valuation metric in isolation.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-23
The company secured back-to-back large contracts in January 2026 with Dongkwang Pharm (KRW 4.29 billion) and Ownerve (KRW 2.25 billion), each representing 20-40% of the prior year's revenue on a single-contract basis. These are confirmed contracts that can underpin future quarterly revenue recognition.
Diversification of counterparties across pharmaceutical and herbal bio sectors also reduces reliance on any single customer.
The operating margin rose sharply to 31.3% in 2025 from 20.9% the prior year, showing clear profitability improvement. The debt ratio stands at a very low 5.8% with almost no borrowing burden, limiting external funding risk.
This financial soundness can serve as a stable buffer amid a business structure where results swing with contract size.
Multiple market research firms project the freeze-drying equipment market to grow at an annual rate of roughly 5-8%, citing expanding production of biologics and vaccines as a key driver.
If domestic and overseas pharmaceutical and biotech companies continue expanding production facilities, demand for related equipment has the potential to grow accordingly. The company's shift toward a country-by-country direct sales structure to expand overseas revenue could also align with this trend.
Freeze dryers are supplied on a custom-built, installed basis, causing quarterly results to swing significantly depending on contract recognition timing.
Q1 2026 revenue of KRW 2.52 billion, sharply lower than both the prior quarter's KRW 4.23 billion and the following quarter's KRW 4.17 billion, illustrates this pattern. Such volatility makes it difficult to judge a trend from any single quarter's results alone.
Revenue of KRW 20.43 billion in 2022 marked the highest level of the past four years, while 2025 revenue of KRW 14.53 billion remains below that peak. Revenue fell to a trough of KRW 10.82 billion in 2024, so whether the recent recovery translates into a sustained growth trend requires further confirmation.
Global major players such as GEA, Tofflon, and SP Industries have been launching new products with enhanced automation and digital monitoring features in succession, intensifying technological competition.
On large overseas projects, gaps in technology and capital scale versus these players could work against the company in order competition. It may take time for the company's overseas revenue expansion strategy to translate into tangible results.
With single contracts repeatedly reaching 20-40% of annual revenue, cancellation or delivery delays involving a particular large customer could significantly impact results. Revenue stability may be undermined if contract counterparties remain concentrated among a small number of large clients.
Given exports to around 100 countries and a dedicated overseas sales subsidiary structure, the company is exposed to exchange rate fluctuations as well as overseas regulatory approval and logistics risks. The transition to country-by-country direct sales could also entail upfront cost burdens.
Freeze dryer orders depend heavily on customers' new capital investment or GMP certification renewal timing, meaning a broad slowdown in pharmaceutical and biotech industry investment could create order gaps.
This represents a structural risk where results are tied to external investment cycles regardless of the company's own competitiveness.
This marks the expiration of the contract term with Ownerve; confirming whether the contract has been fulfilled and when related revenue is recognized will be important.
Check whether Q3 2026 results reflect revenue from the Dongkwang Pharm and Ownerve contracts, and monitor the operating margin trend.
This is the fulfillment deadline for the Dongkwang Pharm contract; the completion of revenue recognition for the KRW 4.29 billion contract amount should be tracked continuously.
Monitor for new single sales/supply contract disclosures, their size, and target region (domestic vs. overseas) to track progress in order diversification.
Ilshin Bio-Base showed a marked year-on-year improvement in both revenue and operating profit in 2025, moving away from the earnings trough of 2024.
The large contracts confirmed with Dongkwang Pharm and Ownerve in early 2026 provide concrete grounds for future revenue recognition, and the stable financial structure characterized by a low debt ratio can help cushion the earnings volatility inherent in this contract-based business.
Still, notable points of caution include the large quarterly earnings swings typical of the freeze dryer business's contract-based revenue structure, and revenue scale that remains below the 2022 peak.
The global freeze-drying equipment market is expected to see mid-to-long-term growth according to multiple research firms, but competition from global leading players remains significant on large overseas projects.
The extent to which recently signed contracts are reflected in Q3 results and whether the operating margin improvement is sustained will likely be key variables for judging the earnings trajectory going forward.
Investment decisions should be made by readers themselves, taking into full account these contract-based earnings characteristics and industry cycle dynamics.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.